CytoSorbents said today that it’s entering the Iranian market with its CytoSorb adsorber through an exclusive distribution agreement with Armaghan Salamat Kish Group.
CytoSorb is designed to reduce excessive levels of inflammatory mediators in cardiac surgery and critically ill patients, the Monmouth Junction, N.J.-based company said.
“We are pleased that Armaghan Salamat Kish will be working with us to bring CytoSorb to hospitalized patients throughout the country. Their extensive experience and established dedicated sales force in our common markets make them an ideal partner and will ensure strong synergy. In addition, we share a common dedication to help those patients in greatest need, wherever they may be,” CEO Dr. Phillip Chan said in a press release.
The deal calls for Armaghan Salamat Kish to distribute CytoSorb for critical care, cardiac surgery and other hospital applications. CytoSorbents said its flagship product is now distributed in 39 countries.
“This is a historic moment. In the past, we have seen many hospitalized patients fall victim to sepsis, the systemic inflammatory response syndrome, and other related critical conditions. At those times, we had wished somebody, someday could do something for them and end this nightmare of the critical care world. Now, we are proud to have this agreement with CytoSorbents to help these patients ourselves. In our pre-marketing studies, CytoSorb therapy has generated a lot of attention and interest from key opinion leaders as a new way to control and manage SIRS, treat bacterial infection and toxemia, and prevent multiple organ failure in life-threatening illnesses and complications of cardiac and transplant surgery. As the CEO of one of the leading medical device distributors in Iran, we are fully-committed to the commercial and humanitarian success of CytoSorb in the country, particularly for patients and their families. As our two companies embrace this opportunity, we are reminded of the words of Jacob Bronowski who said, ‘Science is the acceptance of what works and what does not. That needs more courage than we might think’,” Armaghan Salamat Kish CEO Mohammadreza Hosseini said in a prepared statement.
The deal comes only weeks after Cytosorbents said it inked a strategic European partnership deal with Terumo Corp. (TYO:4543) to commercialize its CytoSorb blood purification adsorber for cardiac surgery applications.
Terumo will gain exclusive rights to distribute the Cytosorb cardiopulmonary bypass procedure pack for intra-operative use during cardiac surgery in France, Sweden, Denmark, Norway, Finland and Iceland, the companies said.
The CytoSorb adsorber has CE Mark approval in the European Union as an extracorporeal cytokine adsorber to reduce the excessive production of inflammatory mediators in a broad range of conditions, including cardiac surgery, Terumo said.